Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any early infantile epileptic encephalopathy in which the cause of the disease is a mutation in the SLC12A5 gene.
Features include: Brain shrinkage (cerebral atrophy), Focal hemiclonic seizure, Delayed CNS myelination, and Inability to walk and 10 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 10 | Brain shrinkage (cerebral atrophy), Focal hemiclonic seizure, Inability to walk |
Muscles | 1 | Brain shrinkage (cerebral atrophy) |
Head and neck | 1 | Secondary microcephaly |
SLC12A5-related epilepsy of infancy with migrating focal seizures (SLC12A5-EIMFS) is characterized by severe early-onset epileptic encephalopathy, with a distinct electroclinical phenotype that is common to all EIMFS regardless of cause. To date nine children have been reported with SLC12A5-EIMFS . Seizures. In the nine children reported, three clinical stages were evident:
Source: GeneReviews — "SLC12A5-Related Epilepsy of Infancy with Migrating Focal Seizures"
SLC12A5 function has not been fully characterized.
Developmental and epileptic encephalopathy, 34 is associated with mutations in the SLC12A5 gene on chromosome 20.
No clear correlation exists between biallelic SLC12A5 variants and phenotype, which may reflect the limited number of affected individuals reported to date.
Source: GeneReviews — "SLC12A5-Related Epilepsy of Infancy with Migrating Focal Seizures"
Since 2010 a description of the characteristic symptoms and findings of epilepsy of infancy with migrating focal seizures (EIMFS) has been included in the classification of epilepsy syndromes by the International League Against Epilepsy. The diagnosis of SLC12A5-EIMFS is established by molecular genetic testing.
SLC12A5-related epilepsy of infancy with migrating focal seizures (SLC12A5-EIMFS) should be considered in children with the following epilepsy and electroencephalogram (EEG) findings and family history.
Epilepsy features
Seizure onset before age six months
Developmental delay or developmental regression with seizure onset
Seizure type
Source: GeneReviews — "SLC12A5-Related Epilepsy of Infancy with Migrating Focal Seizures"
Since first described by , epilepsy of infancy with migrating focal seizures (EIMFS) has been reported in over 170 individuals. EIMFS is genetically heterogeneous. EIMFS can be isolated or have multisystem involvement; both autosomal dominant and recessive inheritance are observed.
Table 2.
Other Disorders to Consider in the Differential Diagnosis of SLC12A5-EIMFS
Disorder | Gene1 | MOI | Comments
Isolated EIMFS
EIEE43(OMIM 617113) | GABRB32 | AD | 1 set of monozygotic twins
EIEE14(OMIM 614959) | KCNT1 | AD3 | Causes 30%-50% of EIMFS4,5,6
EIEE12(OMIM 613722) | PLCB17 | AR8 | 1 individual7
Progressive microcephalyw/seizures cerebral cerebellar atrophy(OMIM 615760) | QARS | AR8 | 2 individuals9
SMC1A-related EIMFS | SMC1A10 | XL | 1 female infant
| SCN1A11,12,13,14 | AD3 | 3 individuals11,12,13,1...
Source: GeneReviews — "SLC12A5-Related Epilepsy of Infancy with Migrating Focal Seizures"
Genetic testing for SLC12A5 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for developmental and epileptic encephalopathy, 34 has been reported in the published literature.
No approved treatments are currently available for developmental and epileptic encephalopathy, 34. The disease remains an area of unmet medical need.
Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with SLC12A5-related epilepsy of infancy with migrating focal seizures (SLC12A5-EIMFS), the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with SLC12A5-EIMFS
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Assess for evidence of failure to thrive. | — |
Eyes | Ophthalmologic eval incl assessment of vision | — |
ENT/Mouth | Assess hearing. | Gastrointestinal/ |
Feeding | Assess swallowing, gastroesophageal reflux, feeding, nutritional status. | Incl assessment by speech language therapist. |
Respiratory | Assess respiratory status for evidence of risk of respiratory infections aspiration. | Preventive measures may be needed (e.g., flu vaccination prophylactic antibiotics in winter). |
Source: GeneReviews — "SLC12A5-Related Epilepsy of Infancy with Migrating Focal Seizures"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "SLC12A5-Related Epilepsy of Infancy with Migrating Focal Seizures"
View trials for developmental and epileptic encephalopathy, 34
Routine monitoring of:
Feeding, nutritional status, swallowing abilities, gastroesophageal reflux, risk of aspiration pneumonia / respiratory infection
Postural problems (resulting from such complications as scoliosis and hip abnormalities) with regular spine and hip x-rays
Effectiveness of seizure control
Development including motor skills, speech/language, and general cognitive and vocational skills
Source: GeneReviews — "SLC12A5-Related Epilepsy of Infancy with Migrating Focal Seizures"
No clinical trials have been registered for developmental and epileptic encephalopathy, 34.
102 publications have been identified in PubMed for developmental and epileptic encephalopathy, 34. Research spans Epidemiology / Natural History (35%), Basic Science / Preclinical (20%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 36 | 35% |
Laboratory research | 20 | 20% |
Research summaries | 13 | 13% |
Patient case studies | 10 | 10% |
Clinical study results | 10 | 10% |
Testing and diagnosis research | 7 | 7% |
New treatment approaches | 5 | 5% |
Other research | 1 | 1% |
Quiroz V (2026). [PMID: 40811633](https://pubmed.ncbi.nlm.nih.gov/40811633/). *Brain*. [Basic Science / Preclinical]
Cioclu MC (2026). [PMID: 42112912](https://pubmed.ncbi.nlm.nih.gov/42112912/). *Epilepsia Open*. [Review / Meta-Analysis]
Li X (2026). [PMID: 41389464](https://pubmed.ncbi.nlm.nih.gov/41389464/). *Seizure*. [Basic Science / Preclinical]
Leitão E (2026). [PMID: 41912934](https://pubmed.ncbi.nlm.nih.gov/41912934/). *Nat Genet*. [Review / Meta-Analysis]
Lemska A (2026). [PMID: 41293911](https://pubmed.ncbi.nlm.nih.gov/41293911/). *Neurol Neurochir Pol*. [Clinical Trial Publication]
GBD 2023 Mental Disorder Collaborators (2026). [PMID: 42167272](https://pubmed.ncbi.nlm.nih.gov/42167272/). *Lancet*. [Review / Meta-Analysis]
Torbati PN (2026). [PMID: 41633218](https://pubmed.ncbi.nlm.nih.gov/41633218/). *Pediatr Neurol*. [Epidemiology / Natural History]
Akkus N (2026). [PMID: 41507692](https://pubmed.ncbi.nlm.nih.gov/41507692/). *Mol Genet Genomic Med*. [Gene Therapy / Novel Therapeutics]
Benítez-Provedo C (2026). [PMID: 42184160](https://pubmed.ncbi.nlm.nih.gov/42184160/). *Epilepsia*. [Case Report / Case Series]
Karnstedt M (2026). [PMID: 41489401](https://pubmed.ncbi.nlm.nih.gov/41489401/). *Epilepsia*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 5:17 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Neurologic eval |
Incl EEG brain MRI. |
Musculoskeletal | Assessment of tone by pediatric rehab specialist /or PT | — |
Development | Developmental assessment | Incl eval of motor skills, speech/ language, general cognitive, vocational skills. Miscellaneous/ |
Other | Consultation w/clinical geneticist /or genetic counselor | PT = physical therapist Seizures. There are no specific treatments for seizures in SLC12A5-EIMFS. Seizures in EIMFS are generally resistant to most anti-seizure medication. |
AI-curated news mentioning developmental and epileptic encephalopathy, 34
Updated Feb 10, 2026
Research highlights citrate's potential as a diagnostic biomarker for SLC13A5-developmental and epileptic encephalopathy. This discovery could enhance early diagnosis and treatment strategies for affected patients.